Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aggressive Treatment of Heart Patients with Cholesterol-lowering Medication

01.09.2004


Treating heart-attack patients earlier with a more aggressive regimen of cholesterol-lowering medicines may help diminish their chances of sustaining more complications later or dying after their heart attack, researchers at UT Southwestern Medical Center at Dallas have found.



The findings, published online today by The Journal of the American Medical Association, show benefits of treating patients who have recently suffered acute coronary syndromes with higher doses of the cholesterol-lowering drugs called statins soon after they experience heart-attack symptoms.

Dr. James de Lemos, assistant professor of internal medicine at UT Southwestern, is lead author of the second of a two-part, collaborative international study called the Aggrastat to Zocor study, or A to Z study. Dr. Michael Blazing of the Duke Clinical Research Institute presented the study Aug. 30 at the European Society of Cardiology meeting in Munich, Germany.


The primary objective of the first phase or the “A” phase was to assess the safety and effectiveness of two different forms of clot-preventing drugs – enoxaparin and unfractionated heparin – in treatment following heart attacks.

The second, or “Z” phase, evaluated two different strategies of treating patients with cholesterol-lowering medicines.

In the past, Dr. de Lemos said, heart-attack patients were stabilized for several weeks or months and placed on low-cholesterol diets before physicians intervened with statin drugs. “Earlier medical protocols called for patients to receive lower dosages of statins later following a heart attack,” said Dr. de Lemos, an investigator in the Donald W. Reynolds Cardiovascular Clinical Research Center at UT Southwestern. “We observed trends that suggested an earlier, more intensive cholesterol-lowering regimen was better than a delayed, less-aggressive regimen.”

The trial – which enrolled patients between December 1999 and January 2003 – followed 4,500 patients at 322 medical facilities spanning 41 different countries. Half of the trial participants received higher dosages of statin drugs soon after a heart attack. The second group was given lower dosages of the same medicines after a longer recovery time following a heart attack.

Patients given statin drugs earlier showed modest improvement in the rate of subsequent death, congestive heart failure, heart attack and stroke compared with patients who received a later start of a lower-dose statin regimen.

According to the study, 14.4 percent of patients in the group that got higher dosages of statins soon after a heart attack suffered other cardiac events such as heart attacks and strokes compared to 16.7 percent of patients receiving later intervention with lower dosages of the cholesterol-lowering drugs.

“Until recently, little information was available about the timing of initiating statin drugs after a heart attack,” Dr. de Lemos said. “The findings from the A to Z trial suggest that statins can be initiated earlier and in dosages well above the typical starting dose.”

Dr. de Lemos also warned that statin drugs must be closely monitored and the dose decreased or discontinued if side effects such as muscle weakness occur. Muscle pain and weakness (myopathy) is an important side effect of statin drugs and was observed in 0.4 percent of patients receiving the highest dose of simvastatin.

Other investigators included Dr. Eugene Braunwald of Brigham and Women’s Hospital in Boston, the paper’s senior author; researchers from Duke Clinical Research Institute; the University of Edinburgh in Scotland; Green Lane Hospital in Aukland, New Zealand; the University of Montreal and Aker Hospital in Oslo, Norway.

The study was supported by a grant from Merck & Co.

| newswise
Further information:
http://www.utsouthwestern.edu

More articles from Health and Medicine:

nachricht Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)

nachricht Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>